These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 21925064)
41. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Jais X; Launay D; Yaici A; Le Pavec J; Tchérakian C; Sitbon O; Simonneau G; Humbert M Arthritis Rheum; 2008 Feb; 58(2):521-31. PubMed ID: 18240255 [TBL] [Abstract][Full Text] [Related]
42. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. Cella G; Vianello F; Cozzi F; Marotta H; Tona F; Saggiorato G; Iqbal O; Fareed J J Rheumatol; 2009 Apr; 36(4):760-7. PubMed ID: 19208592 [TBL] [Abstract][Full Text] [Related]
43. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. de la Mata J; Gomez-Sanchez MA; Aranzana M; Gomez-Reino JJ Arthritis Rheum; 1994 Oct; 37(10):1528-33. PubMed ID: 7524508 [TBL] [Abstract][Full Text] [Related]
44. Clinical efficacy, safety, tolerability, and survival outcome of long-term inhaled iloprost treatment in the management of pulmonary arterial hypertension: Data from prospective multicenter observational OPTION study. Küçükoğlu MS; Hanta İ; Akdeniz B; Güllülü S; Atahan E; Sayın T; Okumuş G; Önen ZP; Yokuşoğlu M; Baygül A Anatol J Cardiol; 2021 Oct; 25(10):721-732. PubMed ID: 34622787 [TBL] [Abstract][Full Text] [Related]
45. Effects of long-term iloprost treatment on right ventricular function in patients with Eisenmenger syndrome. Chon MK; Cho KI; Cha KS; Seo JS; Kim DS J Cardiol; 2017 May; 69(5):741-746. PubMed ID: 27492657 [TBL] [Abstract][Full Text] [Related]
49. Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension. Reichenberger F; Mainwood A; Morrell NW; Parameshwar J; Pepke-Zaba J Pulm Pharmacol Ther; 2011 Feb; 24(1):169-73. PubMed ID: 20601049 [TBL] [Abstract][Full Text] [Related]
50. Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. Hoeper MM; Gall H; Seyfarth HJ; Halank M; Ghofrani HA; Winkler J; Golpon H; Olsson KM; Nickel N; Opitz C; Ewert R Eur Respir J; 2009 Jul; 34(1):132-7. PubMed ID: 19251782 [TBL] [Abstract][Full Text] [Related]
51. Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group. Airò P; Rossi M; Scarsi M; Danieli E; Grottolo A; Zambruni A Clin Exp Rheumatol; 2007; 25(5):722-7. PubMed ID: 18078620 [TBL] [Abstract][Full Text] [Related]
52. Pulmonary arterial hypertension in connective tissue diseases. Yoshida S Allergol Int; 2011 Dec; 60(4):405-9. PubMed ID: 22015567 [TBL] [Abstract][Full Text] [Related]
53. Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease. Galiè N; Denton CP; Dardi F; Manes A; Mazzanti G; Li B; Varanese L; Esler A; Harmon C; Palazzini M Int J Cardiol; 2017 May; 235():67-72. PubMed ID: 28279499 [TBL] [Abstract][Full Text] [Related]
54. Pulmonary hypertension secondary to systemic lupus erythematosus: prolonged survival following treatment with intermittent low dose iloprost. Mok MY; Tse HF; Lau CS Lupus; 1999; 8(4):328-31. PubMed ID: 10413214 [TBL] [Abstract][Full Text] [Related]
55. Prediction of Future Overt Pulmonary Hypertension by 6-Min Walk Stress Echocardiography in Patients With Connective Tissue Disease. Kusunose K; Yamada H; Hotchi J; Bando M; Nishio S; Hirata Y; Ise T; Yamaguchi K; Yagi S; Soeki T; Wakatsuki T; Kishi J; Sata M J Am Coll Cardiol; 2015 Jul; 66(4):376-84. PubMed ID: 26205595 [TBL] [Abstract][Full Text] [Related]
56. Screening for connective tissue disease in pulmonary arterial hypertension. Pagán RJ; Lee AS; Austin CO; Burger CD South Med J; 2014 Oct; 107(10):666-9. PubMed ID: 25279875 [TBL] [Abstract][Full Text] [Related]
57. Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis. Erdogan M; Esatoglu SN; Kilickiran Avci B; Hatemi G Intern Emerg Med; 2024 Apr; 19(3):731-743. PubMed ID: 38378970 [TBL] [Abstract][Full Text] [Related]
58. Raynaud's phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus. Kasparian A; Floros A; Gialafos E; Kanakis M; Tassiopoulos S; Kafasi N; Vaiopoulos G Lupus; 2007; 16(7):505-8. PubMed ID: 17670849 [TBL] [Abstract][Full Text] [Related]
59. Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis. Pan J; Lei L; Zhao C Clin Exp Rheumatol; 2018; 36(6):1095-1102. PubMed ID: 29998831 [TBL] [Abstract][Full Text] [Related]
60. Treatment of vasculitic leg ulcers in connective tissue disease with iloprost. Veale DJ; Muir AH; Morley KD; Belch JJ Clin Rheumatol; 1995 Mar; 14(2):187-90. PubMed ID: 7540526 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]